Published in Oncology Business Week, March 4th, 2007
The company plans to initiate a phase I trial in the first half of 2007.
"This marks an important milestone for Enzon as we continue to focus our efforts on important oncology therapies," said Jeffrey Buchalter, chairman and chief executive officer of the company. "The continued advancement of the HIF-1 alpha program demonstrates our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week